Notice of Intent to Sole Source- Annual Software Subscription License for the EndoTool

The Department of Veterans Affairs (VA) intends to award a sole source contract for an Annual Software Subscription License for the EndoTool Intravenous (IV) insulin dosing system, specifically to Monarch Medical Technologies, a self-certified small, disadvantaged business based in Charlotte, North Carolina. The contract, which falls under FAR 13.106-1(b) for single sourcing, is expected to be finalized by July 30, 2025. EndoTool IV is an FDA-approved software that enhances patient care by providing accurate insulin dosing recommendations and integrating seamlessly with hospital electronic medical records (EMR) systems. Interested vendors can respond with their capabilities to meet this requirement by June 30, 2025. The Government emphasizes that this is not a solicitation, and all submissions will inform the decision on potential competitive procurement. Compliance with System for Award Management (SAM) registration is mandatory for eligibility. Overall, this presolicitation notice outlines the VA's need for specialized software aimed at improving diabetes management in hospital settings.

The Department of Veterans Affairs (VA) intends to award a sole source contract for an Annual Software Subscription License for the EndoTool Intravenous (IV) insulin dosing system, specifically to Monarch Medical Technologies, a self-certified small, disadvantaged business based in Charlotte, North Carolina. The contract, which falls under FAR 13.106-1(b) for single sourcing, is expected to be finalized by July 30, 2025. EndoTool IV is an FDA-approved software that enhances patient care by providing accurate insulin dosing recommendations and integrating seamlessly with hospital electronic medical records (EMR) systems. Interested vendors can respond with their capabilities to meet this requirement by June 30, 2025. The Government emphasizes that this is not a solicitation, and all submissions will inform the decision on potential competitive procurement. Compliance with System for Award Management (SAM) registration is mandatory for eligibility. Overall, this presolicitation notice outlines the VA's need for specialized software aimed at improving diabetes management in hospital settings.

The document outlines a justification for a single-source procurement by the Department of Veterans Affairs (VA) for the EndoTool Intravenous (IV) software system, aimed specifically for insulin dosing management at the James H. Quillen Veterans Affairs Medical Center. This acquisition falls under simplified acquisition procedures due to its estimated amount being under the Simplified Acquisition Threshold (SAT) of $250,000. The EndoTool software is uniquely capable of integrating 11 patient-specific physiological factors to enhance clinical decision support for insulin titration. Its distinctive feature, the Estimated Residual Extracellular Insulin (EREI), allows for customized insulin dosing by continually calculating the amount of existing insulin in the bloodstream, a functionality that is not available in other products. This software is also approved for use by the Veterans Healthcare Administration, reinforcing its exclusivity for this procurement. The justification illustrates the VA's commitment to utilizing specialized technology to improve patient care in glycemic management.